Cargando…
Emerging therapies against infections with Pseudomonas aeruginosa
Infections with Pseudomonas aeruginosa have been marked with the highest priority for surveillance and epidemiological research on the basis of parameters such as incidence, case fatality rates, chronicity of illness, available options for prevention and treatment, health-care utilization, and socie...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688719/ https://www.ncbi.nlm.nih.gov/pubmed/31448090 http://dx.doi.org/10.12688/f1000research.19509.1 |
_version_ | 1783442935237312512 |
---|---|
author | Tümmler, Burkhard |
author_facet | Tümmler, Burkhard |
author_sort | Tümmler, Burkhard |
collection | PubMed |
description | Infections with Pseudomonas aeruginosa have been marked with the highest priority for surveillance and epidemiological research on the basis of parameters such as incidence, case fatality rates, chronicity of illness, available options for prevention and treatment, health-care utilization, and societal impact. P. aeruginosa is one of the six ESKAPE pathogens that are the major cause of nosocomial infections and are a global threat because of their capacity to become increasingly resistant to all available antibiotics. This review reports on current pre-clinical and clinical advances of anti-pseudomonal therapies in the fields of drug development, antimicrobial chemotherapy, vaccines, phage therapy, non-bactericidal pathoblockers, outer membrane sensitizers, and host defense reinforcement. |
format | Online Article Text |
id | pubmed-6688719 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | F1000 Research Limited |
record_format | MEDLINE/PubMed |
spelling | pubmed-66887192019-08-23 Emerging therapies against infections with Pseudomonas aeruginosa Tümmler, Burkhard F1000Res Review Infections with Pseudomonas aeruginosa have been marked with the highest priority for surveillance and epidemiological research on the basis of parameters such as incidence, case fatality rates, chronicity of illness, available options for prevention and treatment, health-care utilization, and societal impact. P. aeruginosa is one of the six ESKAPE pathogens that are the major cause of nosocomial infections and are a global threat because of their capacity to become increasingly resistant to all available antibiotics. This review reports on current pre-clinical and clinical advances of anti-pseudomonal therapies in the fields of drug development, antimicrobial chemotherapy, vaccines, phage therapy, non-bactericidal pathoblockers, outer membrane sensitizers, and host defense reinforcement. F1000 Research Limited 2019-08-07 /pmc/articles/PMC6688719/ /pubmed/31448090 http://dx.doi.org/10.12688/f1000research.19509.1 Text en Copyright: © 2019 Tümmler B http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Tümmler, Burkhard Emerging therapies against infections with Pseudomonas aeruginosa |
title | Emerging therapies against infections with
Pseudomonas aeruginosa
|
title_full | Emerging therapies against infections with
Pseudomonas aeruginosa
|
title_fullStr | Emerging therapies against infections with
Pseudomonas aeruginosa
|
title_full_unstemmed | Emerging therapies against infections with
Pseudomonas aeruginosa
|
title_short | Emerging therapies against infections with
Pseudomonas aeruginosa
|
title_sort | emerging therapies against infections with
pseudomonas aeruginosa |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688719/ https://www.ncbi.nlm.nih.gov/pubmed/31448090 http://dx.doi.org/10.12688/f1000research.19509.1 |
work_keys_str_mv | AT tummlerburkhard emergingtherapiesagainstinfectionswithpseudomonasaeruginosa |